As with most disease processes, it is helpful to understand the background of the particular disease. Since Respiratory Distress Syndrome (RDS) and each baby's individual course depend on his particular point of lung development, let's look at the course of pulmonary development from fetal through postnatal life...
The development of the lungs is sequential and occurs in five phases - The embryonic phase occurs between 4 to 5 weeks gestation.
• The main event of this phase is formation of the proximal airway.
• Lung buds appear and begin to divide.
• The pulmonary vein appears during this phase and elongates to join the lung buds.
• The trachea develops, and by the end of this period there areo Three divisions of primitive lobes and bronchi on the right o Two divisions of primitive lobes and bronchi on the left
The pseudoglandular phase occurs between 6 to 17 weeks gestation.
• The main event of this phase is the formation of conducting airways.
• At this time cartilage appears, and the main bronchi develop.
• The tracheobronchial tree branches into the trachea and terminal bronchioles. o After this occurrence, the tree only increases in size and length without additional formation of branches.
• The major lobes of the lungs are identified, and the capillary bed is formed.
o This connects the bronchial blood supply but does not connect with the terminal air sacs.
• The connective tissue, muscle, and lymphatics are identifiable.
The canalicular phase occurs between 17 to 24 weeks gestation.
• The main event of this phase is the formation of the acini.
• During this phase, Type II alveolar epithelial cells that eventually become the alveolar lining begin to appear.
• Capillaries begin to proliferate and invade the walls of the terminal airways.
• The airway structure changes from glandular to tubular and increases in size and length.
• Lung fluid production begins during this period.
o Using extrapolated data derived from studies of lambs, it is believed that the term infant secretes about 250 mL/day of lung fluid o A reduction in amount or loss of lung fluid may result in lung hypoplasia o Lung fluid aids in the - Development and maturation of lung cells  Formation, size, and shape of the air space • Alveolar sacs appear between 24-26 weeks gestation • Keep in mind that during this phase of developmento There is insufficient air-blood surface area for gas exchange o Type II alveolar epithelial cells are incapable of releasing sufficient surfactant to sustain adequate respirations
The terminal phase occurs between 25 to 37 weeks gestation
• The main event of this phase is the development of gas-exchange sites.
• Terminal air sacs appear as an out-pouching of the alveolar ducts, or terminal bronchioles. o The air sacs look like a "bunch of grapes". o The alveolar ducts increase in number and maturity.
• Mature type II alveolar epithelial cells begin to cluster at the alveolar ducts.
• Capillaries and vascularization increase with the eventual fusion of the endothelium and epithelium. o This creates the blood-gas barrier needed to sustain extrauterine life.
• The overall size of the lungs increases quickly.
• At approximately 26-28 weeks, there is sufficient differentiation in the lung structures and cells to allow oxygen exchange to occur. o In other words, extrauterine life can be sustained.
The alveolar phase occurs between 38 weeks gestation and continues through postnatal life until approximately 3 years of age.
• This phase is marked by the expansion of gas-exchange surface area and continued proliferation of the alveoli.
• The alveolar wall and interstitial spaces become very thin, and the single capillary network comes into close proximity to alveolar membrane.
The lungs are elastic organs that contract like a balloon and expel air through the upper airway structures (e.g., bronchi, trachea).
• This natural physiologic tendency of the lungs to contract is known as recoil tendency.
Two factors that contribute to recoil tendency are - Surfactant is the primary surface-active agent present in the lungs, and it greatly reduces the surface tension of water.
It is composed of the following phospholipids -
The role of surface-active phospholipids, such as surfactant, is to - Surfactant prevents atelectasis at the end of expiration and facilitates elastic recoil on inspiration, stabilizing the lungs to maintain acceptable blood gas pressures and decrease the work of breathing.
Changing levels of surfactant components can aid in determining fetal lung maturity.
• Lecithin and phosphatidylinositol (PI) levels remain low until about 26-30 weeks' gestation. o These levels increase rapidly after this and peak at 36 weeks gestation.
• Sphingomyelin levels remain stable, with a small peak occurring between 28-30 weeks gestation.
• Phosphatidylglycerol (PG) appears at about 35-36 weeks gestation and increases until term.
o Some health care providers question if this is more indicative of lung maturity than the lecithin/sphingomyelin (L/S) ratio.
The L/S ratio may be used to assess lung maturity.
• A ratio of >2:1 is considered a mature ratio. • Chronic fetal stress accelerates surfactant production allowing for a mature L/S ratio in premature infants.
Other Factors Affecting Fetal Lung Development
Glucocorticoids affect surfactant synthesis and enhance elastin and collagen production which improves lung compliance.
• Glucocorticoids have demonstrated a positive effect on lung maturation and may be useful in minimizing or preventing RDS.
• The administration of antenatal steroids is most effective in the fetus ~ 27-34 weeks gestation when given at least 48 hours prior to but no longer than 7 days prior to delivery.
• The primary steroids used are betamethasone or dexamethasone and are given as a multidose series, not a single dose. o Betamethasone is usually considered the first steroid choice because of improved safety and effectiveness. o Dosage and dosing interval may vary with the specific drug selected.
• Antenatal steroids may be given along with tocolytic agents used to stop premature labor. Catecholamines stimulate the secretion of surfactant into the alveolar space.
• This results in an increase in surfactant and saturated phosphatidylcholine (PC) in the lung fluid and improved lung stability. o This is supported by an increased L/S ratio.
• Catecholamines inhibit fetal lung fluid secretion and promote reabsorption of the fluid within the alveoli at the time of delivery. o These processes work together to prepare the fetus for the transition to pulmonary-based respirations.
Hyperinsulinemia inhibits surfactant development in the infant of the poorly controlled diabetic mother.
• Fetal hyperinsulinism adversely affects fetal lung maturation by antagonizing the action of cortisol. The following prerequisites must be met for gas exchange to occur -
• Ample terminal air sac development to provide adequate surface area for gas exchange.
• Thinning of the alveolar walls to support effective gas exchange of O2 and CO2.
• Approximation of the capillaries and terminal air sacs for effective gas exchange.
• Adequate surfactant production to stabilize the alveoli.
In theory, the fetus does not have respirations because there is no air to breathe in the amniotic fluid, but respiratory movements do occur and begin around the end of the first trimester.
• In utero, tactile stimuli, like brushing against uterine wall or movement of the cord, and fetal asphyxia trigger these movements.
• For unknown reasons, these respiratory movements usually disappear during the third trimester.
During the third trimester, the lungs remain collapsed.
• This minimizes filling of the lungs with fluid and/or debris found in the amniotic fluid, but the alveolar epithelium does secrete small amounts of fluid into the alveoli up to the time of delivery. o This helps to maintain only clean fluid in the lungs.
At birth, the infant begins to breathe within seconds after delivery and establishes normal respiratory effort during the first minute of life.
• Effective respirations with sufficient inspiratory pressures open the alveoli. o Newborns are usually able to generate sufficient inspiratory pressures to accomplish this feat.
• Once the alveoli are opened, the respiratory effort needed to maintain open alveoli is minimal. o This means the second and subsequent breaths are much easier for the infant.
Certain "at risk" infants are unable to accomplish this transition and develop respiratory distress syndrome (RDS) during the early hours of life.
• Since type II pneumocytes do not secrete surfactant until the last 1-3 months of gestation, premature and even a few term infants are "at risk" for developing RDS.
Respiratory distress syndrome (RDS) is a disorder of the lungs that appears at or shortly after birth.
• RDS is primarily a disease of immaturity of the anatomy and physiology of the lungs.
• The alveolar epithelium fails to secrete an adequate amount of surfactant to decrease the surface tension of the alveolar fluid and allow easy alveolar opening during inspiration.
RDS is the most common cause of respiratory failure in the newborn.
• Approximately 40,000 infants per year are affected by RDS.
Other historical names for RDS include hyaline membrane disease (HMD) and MikityWilson Disease.
So, what exactly is going on?
Anatomically, the premature infant's pulmonary structures and alveoli are not sufficiently developed.
• There is a diminished pulmonary capillary bed and surface area for gas exchange.
• The interstitial distance is increased between the alveolar and endothelial cell membranes, making gas exchange more difficult.
• The lungs have an inability to maintain expansion.
• Therefore, the lung tissue is unable to support oxygenation and ventilation.
Physiologically, surfactant production and excretion is insufficient to maintain alveolar stability and prevent alveolar collapse.
• This reduces lung compliance which prevents the establishment of a normal functional residual after each breath. The incidence of RDS is inversely related to gestational age.
• So, the lower the gestational age of the infant, the higher the incidence of RDS.
RDS affects ~ 10% of all premature infants
• The majority of infants who develop RDS are born at <28 weeks gestation.
RDS occurs more frequently in males with a ratio of 2:1 (male:female).
Risk Factors
There are multiple risk factors that predispose an infant to develop RDS. Those risk factors include - • Siblings of a former low birthweight infant with a history of RDS Frequently, the infant who presents with RDS is the preterm infant who appears to be of an appropriate for gestational age (AGA) size, with good Apgar scores, and otherwise looks healthy.
• Respiratory distress begins shortly after birth with worsening pulmonary insufficiency during the first 24 to 48 hours of life.
• The infant presents with increasing respiratory difficulty with results in hypoxia and hypoventilation.
There are several differential diagnoses to consider when assessing respiratory distress. Potential diagnoses include - • Arterial blood gases (ABGs) demonstrateo Hypoxemia -PaO2 < 50 mmHg in room air o Hypercapnea or hypercarbia -increased PaCO2 level o Acidosis -may have respiratory, metabolic, or mixed causes • An echocardiogram may be done to evaluate for the presence of a PDA.
• Laboratory tests o Hemoglobin (Hgb) helps to rule out anemia and polycythemia as the cause of respiratory distress. o CBC with differential and C-reactive protein (CRP) may be used to rule out sepsis.
o Electrolytes help to rule out hypo/hypernatremia, hypocalcemia, hypoglycemia as possible causes of respiratory distress.
RDS is a disease that is self-limited until the infant can produce adequate amounts of surfactant at about 48-72 hours of age.
Of course, the best course of action is to prevent or lessen the course of RDS. This may be accomplished by -
• Administration of antenatal steroids.
• Use of L/S ratio, fetal lung maturity, and PG determination to assist in timing for labor induction or elective Cesarean birth.
• No elective deliveries prior to 39 weeks gestation.
• Perinatal management to avoid pulmonary circulation compromise in the infant. 
RDS treatment goals are to -
• Provide sufficient support to prevent atelectasis of alveoli, hypoxia, hypoxemia, and hypercapnea.
• Prevent additional lung injury.
Surfactant Replacement Therapy and Respiratory Support
The benefits of surfactant replacement therapy include -
• Reduced in mortality and morbidity • Improved lung compliance and decreased resistance which reduces the pressure required to inflate the lungs and decreases the infant's work of breathing • Improved ventilation which increases PaO2, decreases right-to-left intrapulmonary shunting, and improves overall oxygenation Available FDA approved surfactant products include -
Surfactant replacement requires endotracheal intubation for administration.
• However, there is an alternative surfactant administration where the infant is intubated, surfactant is given, and the infant is extubated. This is known as the INSURE technique.
The previous standard of treatment for RDS was mechanical ventilation.
• This treatment is invasive and damages the lungs further and may lead to bronchopulmonary dysplasia (BPD).
The immaturity and vulnerability of preterm infant lungs in combination with mechanical ventilation contribute to barotrauma, volutrauma, and oxygen toxicity.
• This creates injury that can lead to pulmonary edema, inflammation, and fibrosis which increases the risk of infection and the need for long-term oxygen therapy.
Currently, the goal of respiratory support is to transition the infant to continuous positive airway pressure (CPAP) as soon as possible to minimize the length of time on mechanical ventilation. CPAP can help to - CPAP is most often given through the nasal route and may be used in conjunction with caffeine citrate.
• Caffeine is used for its respiratory stimulation properties.
The degree of respiratory support required varies for each infant. Some infants may require mechanical ventilation, while others require CPAP or high-flow nasal cannula.
• Mechanical ventilation may be used for infants with profound hypoxemia and/or hypercapnea.
Oxygenation is monitored through pulse oximetry, and oxygen should be titrated based upon target saturations for the infant - Pulmonary status may also be monitored with chest x-rays as needed. X-rays help -
• Document improvement or deterioration of disease.
• Validate endotracheal tube and umbilical line placement.
• Keep these basic principles in mind when administering inotropes -
• If the infant is hypovolemic, provide volume first.
• Administration through a central venous line is preferred, but inotropes may be given through a large vein IV. o Monitor the peripheral IV site frequently for signs of extravasation.
• The infusion is given continuously on an IV pump.
• Begin the infusion at lower doses and titrate to the infant's response.
• Monitor the infant's HR and BP closely.
Fluid and Nutrition
Adequate treatment of RDS includes provision of appropriate fluids and electrolytes. This includes the following - Use of a humidified isolette is beneficial because it helps to prevent heat and insensible water loss through conduction, convection, evaporation, and radiation.
• A relative humidity of > 85% can reduce transepidermal water loss during the first week of life of the preterm infant to levels that approximate those of a more mature infant.
Pain Management
Intubation, mechanical ventilation, and endotracheal suctioning are considered painful procedures. Therefore, comfort measures and analgesia should be incorporated into care of the infant.
Frequently used medications include fentanyl and morphine. However, the effectiveness of analgesia for preterm infants is unclear and may also have long-term consequences of which we are not currently aware.
Non-pharmacologic interventions that can be used alone or in combination with analgesics include -
• Facilitated tucking such as swaddling • Non-nutritive sucking • Non-noxious sensory stimulation to alleviate pain • Skin-to-skin care with parents as the baby's condition allows Some facilities may use oral sucrose as a pain relief measure. However, additional research is needed in its use in the preterm infant.
The infant with RDS can develop both acute and chronic complications that can occur from -
• Disease process • Treatment OR • Both
To decrease the risk of complications, it is important to begin treatment with the least invasive therapy first and progress to more complicated treatment as the course of the infant's condition dictates.
Potential acute complications of RDS include - 
